idrasil

Cannabinoid-focused biopharmaceutical company C3 Pharmaceuticals, Inc. announced Wednesday that it has executed a tailored share subscription agreement with GEM Global Yield LLC SCS and is planning on listing on the Canadian Securities Exchange. The California company said it has a commitment of...

Idrasil, a cannabis-based tablet aimed at the medical community, is at the center of a long-running lawsuit filed by the Securities and Exchange Commission against a California cannabis company. The SEC alleges fraud and investor losses in the lawsuit, filed Sept. 28, 2021 against C3 International...

The first recreational cannabis sales were made in  Massachusetts this week, although only two stores — New England Treatment Access, or NETA, in Northampton and Cultivate Holdings in Leicester — were allowed to service customers. “Tuesday was another...

Steele Clarke Smith III is chairman and CEO of C3 International, a post-proof of concept, pre-revenue life sciences company specializing in cannabinoid therapeutics. C3 achieved proof of concept in 2015. “I have been in the financial markets ever since, raising the massive amount of capital...